肝细胞癌血管介入治疗联合靶向和免疫治疗进展

摘要/Abstract

摘要： 以经导管动脉化疗栓塞（TACE）和肝动脉灌注化疗为代表的血管介入治疗是临床治疗不可切除中晚期肝细胞癌（HCC）的主要方式。其中,TACE贯穿于Ⅰb至Ⅲb期HCC的治疗。多靶点的酪氨酸激酶抑制剂及血管生成抑制剂等靶向药物在晚期肝癌的治疗和辅助治疗中发挥了重要作用,临床应用已相当成熟。近年来,以免疫检查点抑制剂为主导的免疫治疗逐渐成为临床研究和应用的新热点。HCC发病率高,多数患者初次就诊时已经处于中晚期。对于此类HCC患者的治疗而言,现有的经血管介入治疗、靶向治疗还是免疫治疗,单一治疗手段疗效并不尽如人意,这使得联合疗法在HCC治疗中的探索成为新趋势。

关键词: 肝细胞癌, 血管介入治疗, 靶向治疗, 免疫治疗, 联合治疗

Abstract: Vascular interventional therapy represented by transcatheter arterial chemoembolization（TACE）and hepatic artery infusion chemotherapy is the main clinical treatment of unresectable hepatocellular carcinoma(HCC). Among them, TACE was used throughout the treatment of stage Ib to IIIb HCC. Targeted drugs such as multi-target tyrosine kinase inhibitors and angiogenesis inhibitors have played an important role in the treatment and adjuvant therapy of advanced liver cancer, and their clinical application has been quite mature. In recent years, immunotherapy led by immune checkpoint inhibitors has gradually become the latest hot spot in clinical research and application. Patients with high rates of HCC, most often found for the first time has been in the middle-late stage. For the treatment of such patients with HCC, existing vascular intervention targeted therapy and immunotherapy, a single treatment curative effect is not very desirable, this makes the combination therapy in treating HCC has become a new trend.

Key words: Hepatocellular carcinoma, Vascular intervention, Targeted therapy, Immunotherapy, Combination therapy

缪伎玄, 靳勇. 肝细胞癌血管介入治疗联合靶向和免疫治疗进展[J]. 肝癌电子杂志, 2023, 10(3): 31-37.

Miao Jixuan, Jin Yong. Progress of vascular intervention combined with targeted therapy and immunotherapy for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 31-37.

参考文献

[1] 中国医疗保健国际交流促进会肝脏肿瘤分会,中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组. 肝细胞癌新辅助及转化治疗中国专家共识 [J/CD]. 肝癌电子杂志, 2022, 9(1): 23-28.
[2] YAMADA R, SATO M, KAWABATA M, et al.Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148(2): 397-401.
[3] LENCIONI R, DE BAERE T, SOULEN M C, et al.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116.
[4] ZOU J H, ZHANG L, REN Z G, et al.Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis[J]. J Digest Dis, 2016, 17(8): 510-517.
[5] QIN S, BAI Y, LIM H Y, et al.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
[6] LI Q J, HE M K, CHEN H W, et al.Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial[J]. J Clin oncol, 2022, 40(2): 150-160.
[7] LYU N, WANG X, LI J B, et al.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)[J]. J Clin oncol, 2022, 40(5): 468-480.
[8] HENDI M, MOU Y, LV J, et al.Hepatic arterial infusion chemotherapy is a feasible treatment option for hepatocellular carcinoma: a new update[J]. Gastrointest Tumors, 2021, 8(4): 145-152.
[9] HUANG A, YANG X R, CHUNG W Y, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1): 146.
[10] YAU T, PARK J W, FINN R S, et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90.
[11] FINN R S, RYOO B Y, MERLE P, et al.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial[J]. J Clin Oncol, 2020, 38(3): 193-202.
[12] WU R Q, LAO X M, CHEN D P, et al. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma [J]. Immunity, 2023, 56(1): 180-192.e11.
[13] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2022年版)[J/CD]. 肝癌电子杂志,2022,9(1):1-22.
[14] CABRERA R, PANNU D S, CARIDI J, et al.The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma[J]. Aliment Parmacol Ther, 2011, 34(2): 205-213.
[15] PARK J W, KOH Y H, KIM H B, et al.Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma[J]. J Hepatol, 2012, 56(6): 1336-1342.
[16] KUDO M, IMANAKA K, CHIDA N, et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14): 2117-2127.
[17] LENCIONI R, LLOVET J M, HAN G, et al.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial[J]. J Hepatol, 2016, 64(5): 1090-1098.
[18] MEYER T, FOX R, MA Y T, et al.Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(8): 565-575.
[19] KUDO M, UESHIMA K, IKEDA M, et al.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501.
[20] WANG Z, WANG E, BAI W, et al.Exploratory Analysis to Identify candidates benefitting from combination therapy of transarterial chemoembolization and sorafenib for first-line treatment of unresectable hepatocellular carcinoma: a multicenter retrospective observational study[J]. Liver Cancer, 2020, 9(3): 308-325.
[21] RAOUL J, DECAENS T, BURAK K, et al. Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): final analysis of OPTIMIS in Europe and Canada [J]. Ann Oncol, 2018, 29(Suppl 8): viii240.
[22] KUDO M, FINN R S, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet (London, England), 2018, 391(10126): 1163-1173.
[23] KUDO M.A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE[J]. Liver Cancer, 2019, 8(5): 299-311.
[24] PENG Z, FAN W, ZHU B, et al.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase iii, randomized clinical trial (LAUNCH)[J]. J Clin Oncol, 2023, 41(1): 117-127.
[25] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
[26] HAN Y, CAO G, SUN B, et al.Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study[J]. BMC Gastroenterol, 2021, 21(1): 393.
[27] WANG H, XIAO W, HAN Y, et al.Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy[J]. J Gastrointest Oncol, 2022, 13(3): 1248-1254.
[28] GONG A, LI X.The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis[J]. World J Surg Oncol, 2022, 20(1): 69.
[29] BIN LIANG E A. TACE combined with apatinib in patients with intermediate and advanced hepatocellular carcionma: a prospective, multi-center, randomized clinical trial[J]. Ann Oncol ,2022, 33: S1455-S1455.
[30] LIU S, ZHAO G, YU G, et al.Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients: Efficacy and safety[J]. J Cancer Res Ther, 2020, 16(5): 1165-1170.
[31] SHEN L, CHEN S, QIU Z, et al.Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis[J]. J Cancer Res Ther, 2020, 16(5): 1063-1068.
[32] BRITTEN C D, GOMES A S, WAINBERG Z A, et al.Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study[J]. BMC Cancer, 2012, 12: 16.
[33] PINTER M, ULBRICH G, SIEGHART W, et al.Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo[J]. Radiology, 2015, 277(3): 903-912.
[34] SMOLKA S, CHAPIRO J, MANZANO W, et al.The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma[J]. Clin Imaging, 2017, 46: 1-7.
[35] SAKR O S, BERNDT S, CARPENTIER G, et al.Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology[J]. J Control Release, 2016, 224: 199-207.
[36] UEDA S, HORI S, HORI A, et al.Retrospective study of the efficacy and safety of chemoembolization with drug-eluting microspheres combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2022, 9: 973-985.
[37] FU R, LI Y, JIANG N, et al.Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies[J]. J Clin Invest 2020, 130(3): 1252-1270.
[38] IKEDA M, SHIMIZU S, SATO T, et al.Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial[J]. Ann Oncol, 2016, 27(11): 2090-2096.
[39] PAN Y, WANG R, HU D, et al.Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials[J]. Front Biosci, 2021, 26(10): 873-881.
[40] HE M, LI Q, ZOU R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-560.
[41] ZHENG K, ZHU X, FU S, et al.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial[J]. Radiology, 2022, 303(2): 455-464.
[42] LIU B J, GAO S, ZHU X, et al.Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma[J]. World J Gastrointest Oncol, 2020, 12(6): 663-676.
[43] IMMUTACE: aphase 2 single-arm, open-label study of transarterial chemoembolization in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma[J]. Gastroenterol Hepatol, 2021, 17(11 Suppl 6): 16-17.
[44] MARINELLI B, KIM E, D'ALESSIO A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study[J]. J Immunother Cancer, 2022, 10(6):e004205.
[45] MEI J, LI S H, LI Q J, et al.Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 167-176.
[46] SONG X, KELLEY R K, KHAN A A, et al.Exposure-response analyses of tremelimumab monotherapy or in combination with durvalumab in patients with unresectable hepatocellular carcinoma[J]. Clin Cancer Res, 2023,29(4):754-763.
[47] HAO M Z, LIN H L, CHEN Q, et al.Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study[J]. Chin J Cancer, 2010, 29(2): 172-177.
[48] HE G, ZHENG C, HUO H, et al.TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis[J]. Int Immunopharmacol, 2016, 40: 436-442.
[49] 徐永茂, 徐冬云, 张南征,等. TACE联合PMCT序贯自身肿瘤疫苗与免疫效应细胞治疗大肝癌临床观察[J]. 中华肿瘤防治杂志, 2013, 20(24): 1928-1932.
[50] 祖余琪, 薛平, 蒋小峰. DC-CIK免疫治疗联合TACE介入治疗晚期肝癌的临床研究[J]. 岭南现代临床外科, 2014, 14(5): 505-508.
[51] LLOVET J M, CASTET F, HEIKENWALDER M, et al.Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19(3): 151-172.
[52] ZHENG L, FANG S, WU F, et al.Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study[J]. Front Molecul Biosci, 2020, 7: 609322.
[53] QU S, ZHANG X, WU Y, et al.Efficacy and safety of TACE combined with lenvatinib plus PD-1 Inhibitors cOMPARED wITH TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study[J]. Front Oncol, 2022, 12: 874473.
[54] CAO F, YANG Y, SI T, et al.The Efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. Front Oncol, 2021, 11: 783480.
[55] WANG H, XIAO W, HAN Y, et al.Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib[J]. J Gastrointest Oncol, 2022, 13(4): 1907-1914.
[56] ZHU H D, LI H L, HUANG M S, et al.Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)[J]. Signal Transduct Target Ther, 2023, 8(1): 58.
[57] HE M K, LIANG R B, ZHAO Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Advanc Med Oncol, 2021, 13: 17588359211002720.
[58] LAI Z, HE M, BU X, et al.Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial[J]. Eur J Cancer (Oxford, England : 1990), 2022, 174: 68-77.
[59] GU Y E A. Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: a prospective, single-arm, phase II trial (TRIPLET study) [J]. Clin Oncol, 2022, 40(Suppl 16): abstr 4106.
[60] SHAOHUA L, JIE M, QIAOXUAN W, et al. Comparing anti-PD-L1 with anti-PD-1 antibodies in the combination of HAlC andLenvatinib for the treatment of unresectable hepatocellular carcinoma [J]. ASCO, 2023, Absract#509.
[61] GALLE P R, FINN R S, QIN S, et al.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001.
[62] LEI Q, YAN X, ZOU H, et al.Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis[J]. Discov Oncol, 2022, 13(1): 95.
[63] 李灵, 贺剑, 谢义星, 等. TACE-HAIC-靶向-免疫四联治疗中晚期肝细胞癌的回顾性对照研究[J]. 中华肝脏病杂志, 2022, 30(9): 939-946.